<bill session="115" type="h" number="6717" updated="2019-04-18T16:27:07Z">
  <state datetime="2018-09-06">REFERRED</state>
  <status>
    <introduced datetime="2018-09-06"/>
  </status>
  <introduced datetime="2018-09-06"/>
  <titles>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to require that the label of drugs with an increased risk of suicide or depression present such increased risk prominently, and for other purposes.</title>
    <title type="short" as="introduced">Depression Side Effect Labeling Awareness Act of 2018</title>
    <title type="short" as="introduced">Depression Side Effect Labeling Awareness Act of 2018</title>
    <title type="display">Depression Side Effect Labeling Awareness Act of 2018</title>
  </titles>
  <sponsor bioguide_id="R000515"/>
  <cosponsors/>
  <actions>
    <action datetime="2018-09-06">
      <text>Introduced in House</text>
    </action>
    <action datetime="2018-09-06" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Consumer affairs"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Mental health"/>
  </subjects>
  <amendments/>
  <committee-reports/>
</bill>
